Cliff Asness's ABUS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 31,741 shares of Arbutus Biopharma Corporation (ABUS) worth $152,358, representing 0.00% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in ABUS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 75,066 shares. Largest reduction occurred in Q1 2019, reducing 93,514 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Arbutus Biopharma Corporation (ABUS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arbutus Biopharma Corporation (ABUS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +7,922 | Add 33.26% | 31,741 | $4.80 |
| Q1 2026 | +7,036 | Add 41.92% | 23,819 | $4.50 |
| Q4 2025 | +1,550 | Add 10.18% | 16,783 | $4.81 |
| Q3 2025 | -22,469 | Reduce 59.60% | 15,233 | $4.54 |
| Q2 2025 | -10,468 | Reduce 21.73% | 37,702 | $3.09 |
| Q1 2025 | -554 | Reduce 1.14% | 48,170 | $3.49 |
| Q4 2024 | +15,006 | Add 44.50% | 48,724 | $3.27 |
| Q3 2024 | +33,718 | New Buy | 33,718 | $3.85 |
| Q4 2023 | -40,598 | Sold Out | 0 | $0.00 |
| Q3 2023 | +26,075 | Add 179.54% | 40,598 | $2.03 |
| Q2 2023 | -6,412 | Reduce 30.63% | 14,523 | $2.30 |
| Q1 2023 | -1,818 | Reduce 7.99% | 20,935 | $3.03 |
| Q4 2022 | -69 | Reduce 0.30% | 22,753 | $2.33 |
| Q3 2022 | +3,392 | Add 17.46% | 22,822 | $1.93 |
| Q2 2022 | +19,430 | New Buy | 19,430 | $2.73 |
| Q3 2021 | -19,036 | Sold Out | 0 | $0.00 |
| Q2 2021 | +19,036 | New Buy | 19,036 | $3.05 |
| Q2 2019 | -28,128 | Sold Out | 0 | $0.00 |
| Q1 2019 | -93,514 | Reduce 76.88% | 28,128 | $3.59 |
| Q4 2018 | +75,066 | Add 161.17% | 121,642 | $3.83 |
| Q3 2018 | +27,354 | Add 142.31% | 46,576 | $9.45 |
| Q2 2018 | +19,222 | New Buy | 19,222 | $7.28 |
Cliff Asness's Arbutus Biopharma Corporation Investment FAQs
Cliff Asness first purchased Arbutus Biopharma Corporation (ABUS) in Q2 2018, acquiring 19,222 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Arbutus Biopharma Corporation (ABUS) for 22 quarters since Q2 2018.
Cliff Asness's largest addition to Arbutus Biopharma Corporation (ABUS) was in Q4 2018, adding 121,642 shares worth $466,000.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 31,741 shares of Arbutus Biopharma Corporation (ABUS), valued at approximately $152,358.
As of the Q2 2026 filing, Arbutus Biopharma Corporation (ABUS) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Arbutus Biopharma Corporation (ABUS) was 121,642 shares, as reported at the end of Q4 2018.